Summit Therapeutics Inc. (SMMT) Financial Statements

Executive TeamFinancials
Shareholders

Summit Therapeutics financial statements at a glance

Summit Therapeutics reported revenue of $0 for fiscal year 2025 (ended December 31, 2025). Net income was -$1.08 billion.

At the end of fiscal year 2025 it had total assets of $751.18 million, total liabilities of $92.32 million and shareholders' equity of $658.86 million, with cash and short-term investments of $713.45 million and total debt of $20.89 million.

Its operations brought in -$322.93 million of cash; capital spending was $657,000, leaving free cash flow of -$323.59 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

SMMT logo

Summit Therapeutics Inc.

SMMTUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Operating Expense
1.09B
Prev Year: 225.97M
YoY: +384.3%
Cost of Revenue
-
Selling General and Administrative
556.70M
Prev Year: 60.50M
YoY: +820.2%
General and Administrative Expense
556.70M
Prev Year: 60.50M
YoY: +820.2%
Other General and Administrative
20.00M
Prev Year: 10.80M
YoY: +85.2%
Research and Development
537.67M
Prev Year: 165.78M
YoY: +224.3%
Operating Income
-1.09B
Prev Year: -225.97M
YoY: -384.3%
Gross Profit
-
Other Income Expense
14.84M
Prev Year: -97.0K
YoY: +15396.9%
Other Non-operating Income (expense)
-53.0K
Pre-tax Income
-1.08B
Prev Year: -221.29M
YoY: -387.8%
Net Income Common Stockholders
-1.08B
Prev Year: -221.31M
YoY: -387.8%
Provision for Income Taxes
-
Net Income
-1.08B
Prev Year: -221.31M
YoY: -387.8%
Net Income Including Non-Controlling Interests
-1.08B
Prev Year: -221.29M
YoY: -387.8%
Net Income from Continuing Operations
-1.08B
Prev Year: -221.29M
YoY: -387.8%
Net Income from Continuing and Discontinued Operation
-1.08B
Prev Year: -221.31M
YoY: -387.8%
Normalized Income
-1.09B
Prev Year: -221.22M
YoY: -394.8%
Basic EPS
-
Prev Year: -0.31
EBIT
-1.08B
Prev Year: -212.60M
YoY: -407.8%
Weighted Average Shares (diluted)
-
Prev Year: 718.54M
EBITDA
-1.08B
Prev Year: -212.51M
YoY: -407.9%
Total Operating Income as Reported
-
Prev Year: -226.00M
Reconciled Depreciation
146.0K
Prev Year: 89.0K
YoY: +64.0%
Net Income from Continuing Operation Net Minority Interest
-1.08B
Prev Year: -221.31M
YoY: -387.8%
Normalized EBITDA
-1.09B
Prev Year: -212.42M
YoY: -415.2%
Total Unusual Items
14.89M
Prev Year: -97.0K
YoY: +15451.5%
Total Unusual Items Excluding Goodwill
14.89M
Prev Year: -97.0K
YoY: +15451.5%
Total Expenses
1.09B
Prev Year: 225.97M
YoY: +384.3%
Diluted NI Available to Com Stockholders
-1.08B
Prev Year: -221.31M
YoY: -387.8%
Gain on Sale of Securities
14.89M
Prev Year: -97.0K
YoY: +15451.5%
Salaries and Wages
536.70M
Prev Year: 49.70M
YoY: +979.9%
Reconciled Cost of Revenue
-
Values in USD

Summit Therapeutics key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$0$0$0$705,000$1.8M
Operating income-$1.1B-$226.0M-$609.7M-$63.6M-$86.2M
Net income-$1.1B-$221.3M-$614.9M-$78.8M-$88.6M
Diluted EPS–-$0.31-$0.99-$0.41-$0.96
Total assets$751.2M$435.6M$202.9M$664.2M$113.4M
Total liabilities$92.3M$46.8M$125.3M$537.5M$30.1M
Shareholders' equity$658.9M$388.7M$77.7M$126.7M$83.3M
Cash and short-term investments$713.4M$412.3M$186.2M$348.6M$71.8M
Total debt$20.9M$7.2M$106.1M$518.8M$2.8M
Operating cash flow-$322.9M-$142.1M-$76.8M-$41.6M-$72.6M
Capital spending$657,000$139,000$128,000$624,000$306,000
Free cash flow-$323.6M-$142.2M-$76.9M-$42.2M-$72.9M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Summit Therapeutics's revenue in fiscal year 2025?

$0.

How much profit does Summit Therapeutics make?

Summit Therapeutics reported net income of -$1.08 billion for fiscal year 2025; operating income was -$1.09 billion.

How much cash and debt does Summit Therapeutics have?

At the end of fiscal year 2025: cash and short-term investments of $713.45 million and total debt of $20.89 million.

What is Summit Therapeutics's free cash flow?

-$323.59 million in fiscal year 2025 (operating cash flow of -$322.93 million minus capital spending of $657,000).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube